Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Saved in:
Bibliographic Details
Title: Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.
Authors: Awasthi R; BioMedical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ., Grupp SA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Division of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA., Waldron ER; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Yanik GA; Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI., Tam CS; Peter MacCallum Cancer Centre, Alfred Hospital and Monash University, Melbourne, VIC, Australia., Rives S; Leukemia and Lymphoma Department, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain.; Institut de Recerca Sant Joan de Déu, Barcelona, Spain., McGuirk JP; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS., Pulsipher MA; Intermountain Primary Children's Hospital Division of Hematology and Oncology, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT., Jaeger U; Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Vienna General Hospital, Medical University of Vienna, Vienna, Austria., Myers GD; Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO., Borchmann P; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Stefanski HE; National Marrow Donor Program, Minneapolis, MN., Bishop MR; The David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL., Chakraborty A; BioMedical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ., Masood A; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Baruchel A; Hématologie-Immunologie Pédiatrique, Hôpital Universitaire Robert Debré, Assistance Publique-Hôpitaux de Paris and Université Paris Cité, Paris, France., Waller EK; Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA.
Source: Blood advances [Blood Adv] 2025 Sep 09; Vol. 9 (17), pp. 4405-4414.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024014995